Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 7 | 2023 | 225 | 2.690 |
Why?
|
| Humans | 60 | 2026 | 16832 | 1.930 |
Why?
|
| Ethnic Groups | 5 | 2021 | 418 | 1.390 |
Why?
|
| Anti-Bacterial Agents | 6 | 2026 | 145 | 1.350 |
Why?
|
| Hospitalization | 9 | 2022 | 816 | 1.340 |
Why?
|
| Vaccination | 12 | 2022 | 725 | 1.330 |
Why?
|
| Urinary Tract Infections | 4 | 2022 | 16 | 1.300 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2022 | 515 | 1.300 |
Why?
|
| Male | 34 | 2026 | 9556 | 1.280 |
Why?
|
| Coccidioidomycosis | 2 | 2020 | 5 | 1.180 |
Why?
|
| California | 20 | 2026 | 2244 | 1.160 |
Why?
|
| Meningococcal Vaccines | 4 | 2019 | 40 | 1.150 |
Why?
|
| Child | 17 | 2022 | 2433 | 1.130 |
Why?
|
| Female | 35 | 2026 | 12193 | 1.090 |
Why?
|
| Influenza, Human | 3 | 2022 | 292 | 1.060 |
Why?
|
| Adult | 24 | 2026 | 7255 | 1.050 |
Why?
|
| Lactams | 2 | 2024 | 2 | 1.010 |
Why?
|
| Proline | 2 | 2024 | 5 | 1.010 |
Why?
|
| Leucine | 2 | 2024 | 4 | 1.010 |
Why?
|
| Nitriles | 2 | 2024 | 7 | 1.010 |
Why?
|
| Retrospective Studies | 16 | 2026 | 2463 | 1.010 |
Why?
|
| Adolescent | 17 | 2022 | 3464 | 0.980 |
Why?
|
| Monkeypox virus | 1 | 2026 | 1 | 0.960 |
Why?
|
| Homosexuality, Male | 1 | 2026 | 38 | 0.940 |
Why?
|
| Child, Preschool | 13 | 2022 | 1430 | 0.920 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2015 | 13 | 0.870 |
Why?
|
| RNA, Messenger | 2 | 2022 | 66 | 0.870 |
Why?
|
| Herpes Zoster Vaccine | 5 | 2016 | 60 | 0.820 |
Why?
|
| Seizures, Febrile | 2 | 2014 | 42 | 0.820 |
Why?
|
| Herpes Zoster | 5 | 2016 | 80 | 0.800 |
Why?
|
| Aged | 19 | 2022 | 5901 | 0.800 |
Why?
|
| Young Adult | 14 | 2026 | 2456 | 0.770 |
Why?
|
| Emergency Service, Hospital | 6 | 2022 | 393 | 0.760 |
Why?
|
| United States | 14 | 2023 | 3858 | 0.760 |
Why?
|
| Streptococcal Infections | 3 | 2014 | 23 | 0.750 |
Why?
|
| Infant | 11 | 2022 | 1212 | 0.730 |
Why?
|
| Latent Tuberculosis | 1 | 2022 | 13 | 0.730 |
Why?
|
| Whooping Cough | 4 | 2022 | 71 | 0.730 |
Why?
|
| Tuberculosis | 1 | 2022 | 23 | 0.720 |
Why?
|
| Orthopedic Procedures | 1 | 2022 | 6 | 0.710 |
Why?
|
| Outpatients | 2 | 2020 | 99 | 0.710 |
Why?
|
| Middle Aged | 20 | 2022 | 7515 | 0.690 |
Why?
|
| Durable Medical Equipment | 1 | 2021 | 1 | 0.680 |
Why?
|
| Cohort Studies | 11 | 2023 | 2396 | 0.660 |
Why?
|
| Minority Groups | 1 | 2021 | 99 | 0.640 |
Why?
|
| Antifungal Agents | 1 | 2020 | 3 | 0.630 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.620 |
Why?
|
| Health Status Disparities | 1 | 2021 | 145 | 0.600 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.600 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.600 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 137 | 0.580 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 1887 | 0.570 |
Why?
|
| Vaccines, Conjugate | 3 | 2019 | 59 | 0.550 |
Why?
|
| Coccidioides | 1 | 2018 | 3 | 0.550 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 19 | 0.540 |
Why?
|
| Influenza Vaccines | 3 | 2022 | 300 | 0.540 |
Why?
|
| Obesity | 2 | 2021 | 811 | 0.530 |
Why?
|
| Incidence | 8 | 2022 | 1229 | 0.530 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2022 | 98 | 0.520 |
Why?
|
| Meningitis, Meningococcal | 2 | 2017 | 6 | 0.510 |
Why?
|
| Escherichia coli | 2 | 2007 | 8 | 0.500 |
Why?
|
| Bacteremia | 2 | 2013 | 11 | 0.490 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.480 |
Why?
|
| Cross Infection | 1 | 2015 | 22 | 0.450 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2015 | 11 | 0.440 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 40 | 0.440 |
Why?
|
| Streptococcus | 2 | 2014 | 2 | 0.430 |
Why?
|
| Risk Factors | 8 | 2020 | 3108 | 0.420 |
Why?
|
| Pharyngitis | 2 | 2010 | 10 | 0.410 |
Why?
|
| Bacterial Typing Techniques | 3 | 2010 | 4 | 0.410 |
Why?
|
| Bordetella | 1 | 2013 | 1 | 0.400 |
Why?
|
| Bordetella Infections | 1 | 2013 | 1 | 0.400 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 15 | 0.400 |
Why?
|
| Ritonavir | 2 | 2024 | 15 | 0.390 |
Why?
|
| Neisseria meningitidis | 1 | 2013 | 10 | 0.390 |
Why?
|
| Livestock | 2 | 2020 | 2 | 0.380 |
Why?
|
| Fever | 3 | 2022 | 52 | 0.340 |
Why?
|
| Case-Control Studies | 3 | 2022 | 995 | 0.330 |
Why?
|
| Streptococcus pyogenes | 1 | 2010 | 6 | 0.330 |
Why?
|
| Carrier State | 1 | 2010 | 7 | 0.330 |
Why?
|
| Genetic Variation | 1 | 2010 | 67 | 0.320 |
Why?
|
| Time Factors | 3 | 2021 | 989 | 0.310 |
Why?
|
| Hospitals | 3 | 2022 | 69 | 0.310 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 58 | 0.310 |
Why?
|
| Ambulatory Care | 2 | 2022 | 205 | 0.300 |
Why?
|
| Agriculture | 1 | 2018 | 7 | 0.290 |
Why?
|
| Occupational Health | 1 | 2018 | 15 | 0.290 |
Why?
|
| Access to Information | 1 | 2018 | 11 | 0.280 |
Why?
|
| Pandemics | 2 | 2020 | 289 | 0.280 |
Why?
|
| Public Health | 1 | 2018 | 80 | 0.270 |
Why?
|
| Adhesins, Escherichia coli | 1 | 2007 | 1 | 0.270 |
Why?
|
| Fimbriae Proteins | 1 | 2007 | 1 | 0.270 |
Why?
|
| Gonorrhea | 2 | 2026 | 20 | 0.260 |
Why?
|
| Animals | 4 | 2020 | 237 | 0.260 |
Why?
|
| Sex Factors | 3 | 2020 | 560 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 28 | 0.250 |
Why?
|
| Algorithms | 2 | 2022 | 210 | 0.250 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 48 | 0.250 |
Why?
|
| Age Factors | 3 | 2020 | 814 | 0.250 |
Why?
|
| Body Mass Index | 2 | 2021 | 925 | 0.240 |
Why?
|
| Comorbidity | 2 | 2020 | 516 | 0.240 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2026 | 2 | 0.240 |
Why?
|
| Doxycycline | 1 | 2026 | 2 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 305 | 0.240 |
Why?
|
| Phylogeny | 1 | 2026 | 18 | 0.240 |
Why?
|
| Headache | 2 | 2022 | 11 | 0.240 |
Why?
|
| Myalgia | 2 | 2022 | 10 | 0.240 |
Why?
|
| Escherichia coli Proteins | 1 | 2005 | 1 | 0.230 |
Why?
|
| Los Angeles | 1 | 2026 | 139 | 0.230 |
Why?
|
| Clostridium difficile | 2 | 2015 | 22 | 0.220 |
Why?
|
| Brazil | 4 | 2014 | 7 | 0.210 |
Why?
|
| Odds Ratio | 2 | 2018 | 569 | 0.210 |
Why?
|
| Antiviral Agents | 1 | 2024 | 92 | 0.190 |
Why?
|
| Neutralization Tests | 1 | 2022 | 3 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2015 | 164 | 0.190 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 13 | 0.190 |
Why?
|
| Chest Pain | 1 | 2022 | 15 | 0.190 |
Why?
|
| Prospective Studies | 1 | 2026 | 1186 | 0.190 |
Why?
|
| Fatigue | 1 | 2022 | 30 | 0.190 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 37 | 0.180 |
Why?
|
| DNA, Bacterial | 3 | 2013 | 10 | 0.180 |
Why?
|
| Drug Combinations | 1 | 2022 | 42 | 0.180 |
Why?
|
| Diphtheria | 1 | 2022 | 13 | 0.180 |
Why?
|
| Tetanus | 1 | 2022 | 23 | 0.180 |
Why?
|
| Influenza A virus | 1 | 2022 | 13 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 70 | 0.180 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2022 | 21 | 0.180 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 67 | 0.180 |
Why?
|
| Organizations | 1 | 2021 | 7 | 0.180 |
Why?
|
| Age Distribution | 3 | 2020 | 221 | 0.170 |
Why?
|
| Aftercare | 1 | 2022 | 46 | 0.170 |
Why?
|
| Electronic Health Records | 3 | 2022 | 702 | 0.170 |
Why?
|
| Electricity | 1 | 2021 | 2 | 0.170 |
Why?
|
| Poverty Areas | 2 | 2010 | 23 | 0.160 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 43 | 0.160 |
Why?
|
| Seasons | 2 | 2022 | 114 | 0.160 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2020 | 8 | 0.160 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 7 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2022 | 152 | 0.150 |
Why?
|
| Medicaid | 1 | 2021 | 189 | 0.150 |
Why?
|
| Population Surveillance | 3 | 2022 | 242 | 0.150 |
Why?
|
| Immunization Schedule | 3 | 2019 | 127 | 0.150 |
Why?
|
| Meningococcal Infections | 1 | 2019 | 17 | 0.150 |
Why?
|
| Continental Population Groups | 1 | 2021 | 255 | 0.150 |
Why?
|
| Sex Distribution | 2 | 2020 | 164 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 353 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2020 | 1047 | 0.140 |
Why?
|
| Immunoassay | 1 | 2018 | 9 | 0.140 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1058 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 290 | 0.130 |
Why?
|
| Hepatitis B Vaccines | 2 | 2014 | 44 | 0.130 |
Why?
|
| Asthma | 1 | 2020 | 375 | 0.130 |
Why?
|
| Risk | 2 | 2015 | 453 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 374 | 0.130 |
Why?
|
| Escherichia coli Infections | 2 | 2007 | 6 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 104 | 0.120 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 12 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 445 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 657 | 0.120 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.120 |
Why?
|
| Policy Making | 1 | 2016 | 14 | 0.120 |
Why?
|
| Hypertension | 1 | 2020 | 475 | 0.110 |
Why?
|
| Poisson Distribution | 1 | 2015 | 84 | 0.110 |
Why?
|
| Managed Care Programs | 2 | 2014 | 275 | 0.110 |
Why?
|
| Immunocompetence | 1 | 2015 | 10 | 0.110 |
Why?
|
| Vaccine Potency | 1 | 2015 | 4 | 0.110 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2015 | 24 | 0.110 |
Why?
|
| Inpatients | 1 | 2015 | 78 | 0.110 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.110 |
Why?
|
| Epilepsy | 1 | 2014 | 14 | 0.110 |
Why?
|
| Genotype | 2 | 2014 | 198 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 2014 | 6 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 144 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 161 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 261 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 149 | 0.100 |
Why?
|
| Maternal Age | 1 | 2014 | 73 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 58 | 0.100 |
Why?
|
| Spleen | 1 | 2013 | 4 | 0.100 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2013 | 2 | 0.100 |
Why?
|
| Molecular Typing | 1 | 2013 | 2 | 0.100 |
Why?
|
| Gestational Age | 1 | 2014 | 118 | 0.100 |
Why?
|
| Urban Population | 2 | 2012 | 105 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2014 | 43 | 0.100 |
Why?
|
| Africa South of the Sahara | 1 | 2013 | 2 | 0.100 |
Why?
|
| Models, Immunological | 1 | 2013 | 2 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 5 | 0.100 |
Why?
|
| Mass Vaccination | 1 | 2013 | 22 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 113 | 0.100 |
Why?
|
| Minnesota | 1 | 2013 | 51 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2013 | 112 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2013 | 108 | 0.090 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 98 | 0.090 |
Why?
|
| HIV Infections | 1 | 2019 | 708 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 489 | 0.090 |
Why?
|
| Oregon | 1 | 2013 | 168 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 410 | 0.090 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2012 | 1 | 0.090 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2012 | 1 | 0.090 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 14 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 5 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 346 | 0.090 |
Why?
|
| Cities | 1 | 2012 | 28 | 0.090 |
Why?
|
| Prevalence | 2 | 2012 | 785 | 0.090 |
Why?
|
| Chlamydia Infections | 2 | 2026 | 24 | 0.080 |
Why?
|
| Syphilis | 2 | 2026 | 18 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 5 | 0.080 |
Why?
|
| Chickens | 1 | 2020 | 6 | 0.080 |
Why?
|
| Neoplasms | 1 | 2014 | 447 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2014 | 693 | 0.070 |
Why?
|
| Community-Based Participatory Research | 1 | 2018 | 45 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2016 | 1098 | 0.070 |
Why?
|
| Sequence Homology | 1 | 2007 | 1 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2007 | 88 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 1233 | 0.060 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2026 | 3 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2022 | 828 | 0.060 |
Why?
|
| Cattle | 1 | 2005 | 10 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 16 | 0.060 |
Why?
|
| African Americans | 2 | 2020 | 394 | 0.050 |
Why?
|
| Cough | 1 | 2022 | 20 | 0.050 |
Why?
|
| Corynebacterium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Temperature | 1 | 2022 | 18 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 20 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 47 | 0.050 |
Why?
|
| Influenza B virus | 1 | 2022 | 13 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2022 | 60 | 0.040 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2022 | 56 | 0.040 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 30 | 0.040 |
Why?
|
| Asian Americans | 1 | 2020 | 146 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 29 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2019 | 73 | 0.040 |
Why?
|
| Vaccines, Combined | 1 | 2019 | 80 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 141 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 400 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2020 | 350 | 0.030 |
Why?
|
| Bell Palsy | 1 | 2017 | 14 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 1555 | 0.030 |
Why?
|
| Stroke | 1 | 2019 | 297 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 97 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2016 | 58 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2015 | 57 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2015 | 84 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 16 | 0.030 |
Why?
|
| Superantigens | 1 | 2014 | 1 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2014 | 1 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 7 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 6 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 14 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 22 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2012 | 3 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2012 | 3 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2014 | 262 | 0.020 |
Why?
|
Concepts
(254)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(32)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->